Noninvasive circulating tumor cell and urine cellular XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphism detection as an effective screening panel for genitourinary system cancers

Cen Wu1, Cheng Xu2, Guaxiu Wang2, Dahu Zhang3, Xiaoyu Zhao2,4

1Department of Urology Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, China; 2Biotecan Medical Diagnostics Co., Ltd, Zhangjiang Center for Translational Medicine, Shanghai 201204, China; 3Department of Urology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China; 4State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China

Contributions: (I) Conception and design: C Wu, X Zhao; (II) Administrative support: D Zhang; (III) Provision of study materials: C Wu, DZ Zhang; (IV) Collection and assembly of data: C Xu, GX Wang; (V) Data analysis and interpretation: C Xu, X Zhao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Xiaoyu Zhao. State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, No. 2005 Songhu Road, Shanghai 200433, China. Email: xyzh07@126.com; Mr. Dahu Zhang. Department of Urology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, No. 15 Jiefang Road, Xiangyang 441000, China. Email: xfyzdh@163.com.

Background: Valid cancer screening and treatment monitoring are critical for cancer patients. Although genitourinary system cancers have a high recurrence rate, when diagnosed, patients undergo surgery promptly. We sought to explore sensitive and noninvasive screening and postoperative recurrence monitoring methods, such as circulating tumor cells (CTCs) or tumor susceptibility gene detection, to determine their appropriateness for genitourinary system cancers.

Methods: We adopted multiple detection methods. Enrichment-immunofluorescence in situ hybridization (SE-iFISH) was employed to detect CTCs from the peripheral blood of patients, and Agena Bioscience MassARRAY was used to detect single-nucleotide polymorphisms (SNPs) in tumor susceptibility genes from urine cells.

Results: In our research, CTCs showed a 76.92% positivity rate among 26 genitourinary system cancer patients, and the number of CTCs was consistent with the stage of cancer. In monitoring for bladder cancer (BC) recurrence, CTCs were more prevalent than urine cytology (66.67% vs. 41.67%). To our surprise, urine cellular XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphisms were specifically found in cancer patients but not in patients with inflammation or in healthy individuals. XPC polymorphism (rs2228001, A2815C) rates were 30.77%, 40%, and 50% in bladder cancer, renal carcinoma, and prostate cancer patients, respectively, and those for XRCC1 (rs25487, G1196A) were 3.85%, 20%, and 25%, respectively.

Conclusions: As a common biomarker, CTCs showed remarkable performance in cancer screening and monitoring. The noninvasive panel comprising CTCs and XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphisms showed high sensitivity (positive rate: 92.86%) and is suitable for genitourinary system cancer screening.

Keywords: Circulating tumor cells (CTCs); XPC; XRCC1; genitourinary system cancers; screening

Submitted Jun 06, 2019. Accepted for publication Oct 10 2019.
doi: 10.21037/tcr.2019.10.47
View this article at: http://dx.doi.org/10.21037/tcr.2019.10.47
Introduction

Genitourinary system cancers, such as bladder cancer, renal carcinoma, and prostate cancer, frequently occur in males. In 2019, there were 61,700, 44,120, and 174,650 new cases of bladder cancer, renal carcinoma, and prostate cancer, respectively, in American males and 18,770, 29,700, and 0 female patients with bladder cancer, renal carcinoma, and prostate cancer, respectively (1). This incidence trend was consistent with that in China (2). Although these patients undergo timely surgical resection, the cancer is likely to recur, and thus long-term monitoring is needed. Therefore, it is crucial to choose highly sensitive and noninvasive indicators to screen and monitor the progression of genitourinary system cancers.

Circulating tumor cells (CTCs), which originate from carcinoma tissue, were first discovered in peripheral blood by the Australian physician Thomas Ashworth in 1869 (3). CTCs have been widely used in cancer screening and monitoring studies, including for breast cancer, small cell lung cancer, bladder cancer, prostate cancer, and other solid tumors (4-7). CTCs from 188 urothelial carcinomas of bladder (UCB) patients were analyzed by the CellSearch system, revealing that patients without CTCs had better relapse-free survival (RFS) than did patients with CTCs detected by histology (P<0.05) (8). In patients with advanced urothelial carcinoma of the bladder, CTCs have been associated with tumor stage, lymph node metastases, and fluorodeoxyglucose positron emission tomography (FDG-PET) findings (9). CTCs have also been used for sunitinib monitoring in metastatic renal cell carcinoma (mRCC), with very good results (10). When discriminating prostate cancer metastasis from nonmetastasis, glucose metabolic (GM) + CTCs presented a higher area under the receiver operating characteristic (ROC) curve (AUC), of 0.780, than did EMT CTC subtypes (E-CTCs 0.729, H-CTCs 0.741, and M-CTCs 0.648) (11). In addition, based on monitoring 6,081 patients, the efficacy of CTC was better than that of SPA in metastatic castration-resistant prostate cancer (12).

Many studies have verified tumor susceptibility genes related to the occurrence and development of cancers. In general, genitourinary system cancers have similar familial syndromes; for instance, hereditary renal cell carcinoma (RCC) exhibits germline mutations in VHL, FLNC, MET, FH, SDHB/C/D, and TSC1/2 (13). Geary et al. found a 3.6 relative risk for bladder cancer (P=0.001) in MutS homolog 2 (MSH2)-positive families compared with MSH2-negative families (14). Furthermore, mutations in EGFR, ERBB2, PTEN, APC, NF1, and BRAF have been identified in mRCC patients based on ctDNA detection, with a correlation with tumor burden (15). However, ctDNA is very easily degraded because of its short half-life of 16 min to 2.5 hours and is hence not an ideal biomarker (16,17). In a genome-wide association study (GWAS), 76 prostate cancer risk SNPs were found; the MYC, MSMB, KLK2 and KLK3 genes, which are clinically relevant, were analyzed with regard to prostate cancer risk (18). The XRCC1 polymorphism rs1799782 (C194T) was reported to correlate with tumor metastasis and molecular subtypes in breast cancer and XRCC1 Arg399Gln with bladder cancer (19,20). In addition, the XPC intron11 C/A polymorphism and Lys939Gln are risk factors for prostate cancer (21,22).

In the process of biomarker detection, different methods may have a considerable impact on detection results. The CellSearch system for CTCs, which is based on positive antibody capture, showed a low detection rate (23), whereas subtraction enrichment-immunofluorescence in situ hybridization (SE-iFISH) displayed better performance (SE-iFISH vs. CellSearch, 91% vs. 38%) (24). SE-iFISH involves subtraction enrichment of hematogenous cells and subsequent removal of red and white blood cells, leaving only CTCs (25). In addition to peripheral blood samples, noninvasive urine cells have been used in recurrence monitoring for bladder cancer, an approach that was completely harmless to patients (26).

To increase the sensitivity and specificity of genitourinary system cancer screening and to avoid causing more trauma to patients, we combined multiple detection methods in this study. SE-iFISH was employed to detect CTCs from peripheral blood samples, and Agena Bioscience MassARRAY was used to reveal mutations or SNPs in tumor susceptibility genes in urine cells. Agena Bioscience MassARRAY is an advanced detection system based on MALDI-TOF MS technology and has a high flux function for detecting dozens of genes in one sample (27). By using multiple detection methods, we hope to improve sensitivity and specificity for genitourinary system cancer screening.

Methods

Patients

Patients were enrolled from two hospitals, Quanzhou First Hospital Affiliated to Fujian Medical University (Fujian, China) and Xiangyang No. 1 People’s Hospital (Hubei, China), from May 2016 to Jan 2019. Permission to use
Peripheral blood and urine samples were obtained from the Ethics Committees of these two hospitals. The study enrolled 87 subjects, including 67 patients and 20 healthy individuals; 77 were male and 10 female, with average age of 61.15 years (Table 1). All patients and healthy individuals signed informed consent before the experiment. Peripheral blood specimens (7.5 mL each) were extracted from 36 patients for SE-iFISH CTCs detection, including 16 bladder cancer patients, 12 renal carcinoma patients, and 8 prostate cancer patients. Urine specimens (50 mL each) were collected from 65 subjects for MassARRAY detection, including 26 bladder cancer patients, 5 renal carcinoma patients, 4 prostate cancer patients, 4 benign bladder tumor patients, 6 prostatitis patients, and 20 healthy individuals.

### Table 1: Participant information

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of participants</th>
<th>% of participants</th>
<th>Average age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
<td>All</td>
</tr>
<tr>
<td>Bladder cancer patients</td>
<td>28</td>
<td>6</td>
<td>34</td>
</tr>
<tr>
<td>Renal carcinoma patients</td>
<td>12</td>
<td>1</td>
<td>13</td>
</tr>
<tr>
<td>Prostate cancer patients</td>
<td>10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Benign bladder tumor patients</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Prostatitis patients</td>
<td>6</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Healthy individuals</td>
<td>17</td>
<td>3</td>
<td>20</td>
</tr>
</tbody>
</table>

**SE-iFISH CTC enrichment and identification**

Subtraction enrichment and identification reagents for analysis of CTCs were provided by the Cytelligen CTC enrichment kit (Cytelligen, San Diego, CA, USA). For CTC subtraction enrichment, briefly, peripheral blood (7.5 mL each) was extracted from 36 patients for SE-iFISH CTCs detection, including 16 bladder cancer patients, 12 renal carcinoma patients, and 8 prostate cancer patients. Urine specimens (50 mL each) were collected from 65 subjects for MassARRAY detection, including 26 bladder cancer patients, 5 renal carcinoma patients, 4 prostate cancer patients, 4 benign bladder tumor patients, 6 prostatitis patients, and 20 healthy individuals.

For CTC identification, the dried cells were treated with 20 μL FR1 and 180 μL FR2 mixture for 10 min and washed twice with FR3. The cells were dehydrated with ethanol. After air drying, 10 μL of probe solution (fluorescence-labeled CEP8 probes) was added to the glass slide, and fluorescence in situ hybridization (FISH) with denaturation at 76 °C for 10 min and hybridization at 37 °C for 4 hours was performed. The cells were then immunostained with anti-CD45 and anti-CK18 antibodies for 2 hours at room temperature. After washing with PBS, the slide was treated with DAPI reagent and observed under a fluorescence microscope (Nikon, Japan). CTCs were confirmed when CK18+CD45+DAPI+CEP8 =2, CK18+CD45+DAPI+CEP8 >2, and CK18+CD45-DAPI+CEP8 >2.

**MassARRAY SNP detection**

MassARRAY iPLEX Gold multiple genotyping analysis (Agena Bioscience, Inc.) reagents (Agena PCR reagent, Agena SAP reagent, and Agena iPLEX reagent) were provided by Agena Bioscience. Briefly, 50 mL of urine was centrifuged 800 xg for 10 min to obtain cells. DNA extraction was performed following the manufacturer’s protocol (TIANGEN, DP348). PCR mixtures were prepared following the Agena PCR reagent set and start PCR procedures, with shrimp alkaline phosphatase (SAP) treatment. After extending the reaction, the samples underwent desalination processing and were added to the chip and analyzed by MALDI-TOF MS.

MassARRAY primers:
- **XPC (rs2228001, A2815C)** F: ACGTTGGATGACGTCTCCCACCTGTTC.
- R: ACGTTGGATGAACTGGTGGGCCCCTCTA.
- **UEP**: ACCTGTTCAGTCCCTTGG.
- **XRCC1** (rs25487, G1196A) F: ACGTTGGATGCACTTCGCTGAGAGTGG.
- ACGTTGGATGACGTCTCCCACCTGTTC.
R: ACGTTGGATGCAGGATAAGGAGCAGG

UEP: CATGCGTCGGCGGCTGCCCTCCC.

Results

SE-iFISH CTCs had excellent sensitive and specific screening effects for genitourinary system cancers

To evaluate the sensitivity and specificity of SE-iFISH CTC detection for cancer screening, 10 healthy individuals and 10 treated patients with genitourinary system cancers (4 BC patients, 4 renal carcinoma patients, and 2 prostate cancer patients) were enrolled for SE-iFISH CTC analysis. Peripheral blood specimens (7.5 mL) were extracted from subjects, and serum, red blood cells, and white blood cells were removed; CTCs were retained for iFISH CTC detection. According to the results, 0 CTCs were detected in the 10 healthy individuals. In contrast, CTCs were found in 70% (7/10) of the patients, with an average number of 4.3/7.5 mL peripheral blood (Figure 1A,B). SE-iFISH CTC detection had very high specificity in distinguishing genitourinary system cancer patients from healthy individuals (Figure 1B).

Next, SE-iFISH CTC detection was performed for 26 preoperative patients, including 12 bladder cancer, 8 renal carcinoma, and 6 prostate cancer patients. We found a CTC positivity rate of 76.92% (20/26), and the average number of CTCs was 5.5/7.5 mL peripheral blood per patient (Table 2). Further analysis revealed that the number of CTCs was consistent with progression of the cancer, with average CTC numbers in tumor stages T1, T2, and T3 of 4.53, 6.00, and 9.00, respectively (Figure 1C). Thus, CTC has high application value in genitourinary system cancer screening and may effectively reflect cancer progression.

XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphisms as an effective complement for CTC screening of genitourinary system cancers

Because urine samples are completely noninvasive and there is ample cancer information in the urine cells of patients, we sought to utilize a new method to study genitourinary system cancer screening by using these noninvasive samples. Many genes involved in genitourinary system cancers, such as XRCC1, XPC, EGFR, ERBB2, APC, TERT, and BRAF, have been studied by the advanced and high-flux MassARRAY iPLEX Gold multiple genotyping analysis system (15,19,21). After preliminary screening, we found that the XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphisms were effectively detected by this system, and these two gene polymorphisms had good specificity for distinguishing cancer patients from noncancer patients and healthy individuals.

A total of 65 subjects, including 26 bladder cancer patients, 5 renal carcinoma patients, 4 prostate cancer patients, 6 benign bladder tumor patients, 6 prostatitis patients, and 20 healthy individuals (Table 3), were evaluated, and we found that positivity rates for XPC A2815C (A>C) of 30.77%, 40%, and 50% among bladder cancer patients, renal carcinoma patients, and prostate cancer patients, respectively, with rates of 3.85%, 20%, and 25% for XRCC1 G1196A (G>A) (Figure 2A). To our surprise, no samples from benign bladder tumor patients, prostatitis patients, and healthy individuals were positive for XPC A2815C and XRCC1 G1196A. Thus, XPC A2815C and XRCC1 G1196A have high specificity in differentiating genitourinary cancer patients from those without cancer.

Despite their high specificity, we found a lower positive rate (50% and 25%) for XPC A2815C and XRCC1 G1196A (Figure 2A) when compared to that of CTCs (76.92%) (Table 2). Therefore, we combined these two detection methods to explore new detection modes. For 14 patients (8 bladder cancer, 4 renal carcinoma, and 2 prostate cancer patients) for whom SE-iFISH CTC and MassARRAY detection was simultaneously conducted, positivity rates were as follows: CTCs 78.57%, XPC A2815C 42.86%, and XRCC1 G1196A 7.12%. After these three biomarkers were combined, the positivity rate reached 92.86%, greatly improving diagnostic efficiency (Figure 2B, Table 4).

SE-iFISH CTC displayed a valid effect on recurrence monitoring for genitourinary system cancer patients

Genitourinary system cancers have a high recurrence rate at 6 months to 2 years after surgery, and effective recurrence monitoring indicators are very important for screening cancer patients. We continued to explore the ability of SE-iFISH CTC to monitor genitourinary system cancers. Among detecting 12 bladder cancer patients with postoperative recurrence, 10 CTC-positive cases (66.67% positivity rate) and 5 urine cytology-positive cases (41.67% positivity rate) were observed (Figure 3A, Table 2).

We then analyzed 5 patients by SE-iFISH CTC to assess their cancer progression at presurgery, 10 days postsurgery,
Figure 1 SE-iFISH CTC evaluation. (A) White blood cell and CTCs, CD45 (red), DNA (blue), CEP8 (orange), and CK18 (green), scale bar: 5 μm. (B) CTCs were detected from 7.5 mL of peripheral blood from 10 patients with genitourinary system cancers, 4 bladder cancer patients, 4 renal carcinoma patients, and 2 prostate cancer patients. (C) CTCs were detected in 26 genitourinary system cancer patients, 12 bladder cancer patients, 8 renal carcinoma patients, and 6 prostate cancer patients, T1 tumor stage patients (n=15), T2 tumor stage patients (n=8), and T3 tumor stage patients (n=3). CTC, circulating tumor cell.
and 6 months postsurgery stages. Patient 1 and patient 2, who experienced early prostatic cancer and showed CTCs preoperatively, CTCs were not detected after 6 months postoperatively, resulting in a good prognosis. In contrast, patient 5 had terminal renal carcinoma and more CTCs with a poor prognosis (Figure 3B). CTCs were detected in patients 3 and 4, who had cancer progression 6 months postsurgery. Therefore, the number of CTCs was consistently accurate and consistent with cancer progression and may be used in cancer monitoring.

Table 2 Information from 26 patients who underwent SE-iFISH CTC detection

<table>
<thead>
<tr>
<th>No.</th>
<th>Sex</th>
<th>Disease</th>
<th>CTCs</th>
<th>Urine cytology</th>
<th>Tumor stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>6</td>
<td>IV</td>
<td>T1N0M0</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>4</td>
<td>V</td>
<td>T1N0M0</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>7</td>
<td>V</td>
<td>T3bN1M0</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>0</td>
<td>IV</td>
<td>T1N0N0</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>Bladder cancer</td>
<td>3</td>
<td>IV</td>
<td>T1N0M0</td>
</tr>
<tr>
<td>6</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>4</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>Bladder cancer</td>
<td>9</td>
<td></td>
<td>T2bN0M0</td>
</tr>
<tr>
<td>8</td>
<td>Female</td>
<td>Bladder cancer</td>
<td>7</td>
<td></td>
<td>T2aN0M0</td>
</tr>
<tr>
<td>9</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>9</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>10</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>6</td>
<td></td>
<td>T2bN0M0</td>
</tr>
<tr>
<td>11</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>0</td>
<td></td>
<td>T2N1M0</td>
</tr>
<tr>
<td>12</td>
<td>Male</td>
<td>Bladder cancer</td>
<td>0</td>
<td></td>
<td>T1bN0M0</td>
</tr>
<tr>
<td>13</td>
<td>Male</td>
<td>Renal carcinoma</td>
<td>9</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>14</td>
<td>Female</td>
<td>Renal carcinoma</td>
<td>12</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>15</td>
<td>Male</td>
<td>Renal carcinoma</td>
<td>3</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>16</td>
<td>Male</td>
<td>Renal carcinoma</td>
<td>5</td>
<td></td>
<td>T1bN0M0</td>
</tr>
<tr>
<td>17</td>
<td>Male</td>
<td>Renal carcinoma</td>
<td>6</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>18</td>
<td>Male</td>
<td>Renal carcinoma</td>
<td>0</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>19</td>
<td>Male</td>
<td>Renal carcinoma</td>
<td>0</td>
<td></td>
<td>T2aN0M0</td>
</tr>
<tr>
<td>20</td>
<td>Male</td>
<td>Renal carcinoma</td>
<td>6</td>
<td></td>
<td>T2aN0M0</td>
</tr>
<tr>
<td>21</td>
<td>Male</td>
<td>Prostate cancer</td>
<td>12</td>
<td></td>
<td>T2cN0M0</td>
</tr>
<tr>
<td>22</td>
<td>Male</td>
<td>Prostate cancer</td>
<td>8</td>
<td></td>
<td>T3bN1M0</td>
</tr>
<tr>
<td>23</td>
<td>Male</td>
<td>Prostate cancer</td>
<td>12</td>
<td></td>
<td>T3bN0M0</td>
</tr>
<tr>
<td>24</td>
<td>Male</td>
<td>Prostate cancer</td>
<td>7</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>25</td>
<td>Male</td>
<td>Prostate cancer</td>
<td>0</td>
<td></td>
<td>T1N0M0</td>
</tr>
<tr>
<td>26</td>
<td>Male</td>
<td>Prostate cancer</td>
<td>8</td>
<td></td>
<td>T2bN0M0</td>
</tr>
</tbody>
</table>

CTC, circulating tumor cell.

**Discussion**

Many CTC detection methods are currently used, such as the CellSearch system, microfluidic isolation, and SE-iFISH. The CellSearch system has showed a low detection rate and sensitivity, and only 38% of CTCs could be detected (24), which is not suitable for CTC testing. Another method, microfluidic isolation, is based on specific antibody expression by CTCs or CTC size (28), however, not every CTC cell expresses tumor marker. SE-iFISH is
Table 3  Participant information for MassARRAY SNP detection

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of participants</th>
<th>% of XPC A2815C</th>
<th>% of XRCC1 G1196A</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
<td>All</td>
</tr>
<tr>
<td>Bladder cancer patients</td>
<td>21</td>
<td>5</td>
<td>26</td>
</tr>
<tr>
<td>Renal carcinoma patients</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Prostate cancer patients</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Benign bladder tumor patients</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Prostatitis patients</td>
<td>6</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Healthy individuals</td>
<td>17</td>
<td>3</td>
<td>20</td>
</tr>
</tbody>
</table>

SNP, single-nucleotide polymorphism.

Figure 2  XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphism detection in genitourinary system cancers. (A) XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphisms in genitourinary system cancer patients. BC (n=26); RC (n=5); PC (n=4); BBT (n=4); prostatitis (n=6); healthy (n=20). (B) Average positive rate of 14 patients (8 bladder cancer patients, 4 renal carcinoma patients, and 2 prostate cancer patients) for XPC A2815C, XRCC1 G1196A, CTCs, and combined diagnosis. BC, bladder cancer patients; RC, renal carcinoma patients; PC, prostate cancer patients; BBT, benign bladder tumor patients; prostatitis, prostatitis patients; healthy, healthy individuals.

Table 4  Participant information for both CTC and MassARRAY SNP detection

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of participants</th>
<th>CTC patients</th>
<th>XPC A2815C patients</th>
<th>XRCC1 G1196A patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
<td>All</td>
<td></td>
</tr>
<tr>
<td>Bladder cancer patients</td>
<td>5</td>
<td>3</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Renal carcinoma patients</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Prostate cancer patients</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

CTC, circulating tumor cell; SNP, single-nucleotide polymorphism.
based on subtractive enrichment, which can enrich more CTCs and shows excellent results (25). The positivity rate for genitourinary system cancer patients in the preliminary experiment was 70%, and that for healthy individuals was 0 (Figure 1B). When a large number of samples were analyzed, CTCs also exhibited a high detection rate (Table 2), and the number of CTCs was directly related to cancer progression (Figure 1C). Unfortunately, we only examined T1, T2, and T3 tumor stage patients. No T4 stage patients were enrolled; therefore, more patients need to be recruited for a more accurate study.

To increase screening sensitivity and without increasing trauma to patients, the MassARRAY iPLEX Gold multiple genotyping analysis system was used, and many cancer susceptibility genes were selected in urine cells (data not shown). Ultimately, XPC A2815C and XRCC1 G1196A were screened out and were able to effectively distinguish cancer patients from those without noncancer (Figure 2A). After combining analysis of XPC A2815C, XRCC1 G1196A, and CTCs, the positivity rate reached 92.86%, and these panels demonstrated excellent screening effectiveness for genitourinary system cancers (Figure 2B). In the course of the study, many cancer-sensitive genes, such as EGFR, ERBB2, TERT, or BRAF, were also selected as candidates; however, they were not used in this study due to their difficult detection or low specificity (mutations were detected in noncancer subjects) (data not shown). Of course, this result cannot exclude their application value and requires further exploration.

CTCs are effective tumor screening and tumor monitoring biomarkers for genitourinary system cancers. Although few clinical case descriptions exist in the literature, validations has been performed in other studies (10,11).

In conclusion, our study revealed that CTCs, which are excellent screening biomarkers, detected by SE-iFISH can be used in genitourinary system cancer screening and monitoring. Based on the MassARRAY system of urine cell detection, noninvasive XPC A2815C and XRCC1 G1196A SNP detection was used as the specific supplement for CTC detection.

Acknowledgments
None.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was approved by the Ethics Committees of Quanzhou First Hospital Affiliated to Fujian Medical University and Xiangyang No. 1 People's Hospital.

References
3. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Medical Journal 1869;14:146-7.

Cite this article as: Wu C, Xu C, Wang G, Zhang D, Zhao X. Noninvasive circulating tumor cell and urine cellular XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphism detection as an effective screening panel for genitourinary system cancers. Transl Cancer Res 2019;8(8):2803-2812. doi: 10.21037/tcr.2019.10.47